Skip to main content
Clinical Trials/NL-OMON53923
NL-OMON53923
Not yet recruiting
Phase 3

A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation. - SCRIPT-AM

Västra Götaland Regionen0 sites30 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Acute Myeloid Leukemia (AML)
Sponsor
Västra Götaland Regionen
Enrollment
30
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Västra Götaland Regionen

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria for randomization part of the study:
  • Age \<\=18 years at time of initial AML, age \<\= 21 years at transplantation.
  • HCT is performed in a study participating center
  • All women of childbearing potential who have to have a negative pregnancy
  • test within 2 weeks prior to the start of treatment.
  • Signed informed consent.
  • Any relapsed AML after initial treatment according to a defined international
  • AML protocol. (NOPHO\-DBH AML 2012/new protocol), or AML in first remission with
  • transplant indications and treatment according to national AML protocol
  • (NOPHO\-DBH AML 2012 or new protocol).

Exclusion Criteria

  • Exclusion criteria for randomization part of the study:
  • Diagnosis of juvenile myelomonocytic leukemia (JMML).
  • History of previous malignancy (AML diagnosed as secondary cancer).
  • Known diagnosis of Fanconi anemia.
  • Prior autologous or allogeneic hematopoietic stem cell transplant.
  • Planned prophylactic DLI or other immunotherapeutic interventions after HCT
  • that are not included in the upfront protocol,
  • Planned anti\-leukemic medication after HCT that are not included in the
  • upfront protocol
  • Known intolerance to any of the chemotherapeutic drugs in the protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials